|Mr. Stefano R. Carchedi||CEO, Pres & Director||718.28k||N/A||1962|
|Mr. Jens Erik Knudsen CPA, M.B.A.||Chief Financial Officer||250k||N/A||1968|
|Mr. James G. Cullem J.D.||Sr. VP of Corp. Devel.||235k||N/A||1969|
|Dr. Marie Foegh DrSc, M.D.||Chief Medical Officer||288k||N/A||1943|
|Mr. Peter Buhl Jensen Adj Professor, M.D., M.D., Ph.D., Ph.D.||Co-Founder||N/A||N/A||1955|
|Dr. Steen Meier Knudsen||Founder & Chief Scientific Officer||N/A||N/A||1961|
|Ms. Ulla Hald Buhl||Founder, COO, Chief IR & Communications||N/A||N/A||1964|
|Mr. Thomas H. Jensen||Founder & Sr. VP of Information Technologies||N/A||N/A||1978|
|Mr. Claus Frisenberg Pedersen||Chief Commercial Officer||N/A||N/A||1972|
|Ms. Annie Rasmussen||Chief of Clinical Operations||N/A||N/A||1957|
Allarity Therapeutics A/S develops various therapeutic candidates for the treatment of cancer using drug-specific companion diagnostics (cDx) generated by its drug response predictor technology. Its lead therapeutic candidate is dovitinib, a second-generation pan-tyrosine kinase inhibitor with the ability to inhibit numerous classes of tumor-driving tyrosine kinases, including FGFR, VEGFR, PDGFR, c-Kit, Flt-3, and CSF-1. The company's therapeutic candidates also include stenoparib, selective inhibitor of the key DNA damage repair enzyme poly-ADP-ribose polymerase; and IXEMPRA, a selective microtubule inhibitor that interferes with cancer cell division through mitotic arrest. It also developing other therapeutic candidates comprising LiPlaCis, a targeted liposomal formulation of Cisplatin; 2X-111, a targeted liposomal formulation of Doxorubicin; and Irofulven, a DNA damaging agent. The company was founded in 2004 and is headquartered in Horsholm, Denmark.
Allarity Therapeutics A/S’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.